Fibrosing Interstitial Lung Disease

• CLINICAL_TRIALS research · 2026-04-21
  Clinical Trial Update: FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression [Phase 3]

  A Phase 3 trial named FIBRONEER-ACT is evaluating nerandomilast for fibrosing interstitial lung disease at risk for progression. The study i…

• CLINICAL_TRIALS research · 2026-04-15
  Clinical Trial Update: A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease [Phase 3]

  Phase 3 clinical trial evaluating nerandomilast in children and adolescents with fibrosing interstitial lung disease to assess tolerability,…

• CLINICAL_TRIALS research · 2025-06-04
  Clinical Trial Update: Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact

  Clinical trial evaluating frailty in patients with fibrosing interstitial lung diseases to determine prognostic and therapeutic impact, with…

• CLINICAL_TRIALS research · 2025-03-03
  Clinical Trial Update: Prospective Cohort of Patients With Fibrosing Interstitial Lung Disease Admitted for Acute Respiratory Failure

  A prospective cohort study is being conducted in patients with fibrosing interstitial lung disease admitted for acute respiratory failure; t…